PolyPid Ltd. (PYPD)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $5.78
- As of
Kresmion compiles this page from PYPD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
PolyPid Ltd. (PYPD): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-28.
See the full PYPD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PYPD on one page. Preview it with sample data, then open it live with a free account.
Preview the PYPD dossierActive events for PYPD
- mediumEarnings above estimates
Q2-2026: Beat consensus by 9.3%, EPS $-0.35 vs $-0.3858 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +294% to PYPD (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +527% to PYPD (2026Q2)
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in PYPD
- mediumEarnings above estimates
Q1-2026: Beat consensus by 20.8% - EPS $-0.35 vs $-0.442 estimate
FREE, NO ACCOUNT
Every event on PYPD, as it fires
You are seeing 5 of 9 events recorded on PYPD since 2026-06-02.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in PYPD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP M8001Q126 · 2026Q2 | $592K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP M8001Q126 · 2026Q2 | $215K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, PYPD
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
PYPD against its peers
PYPD's return on equity of -311.4% ranks in the 14th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-01-31 and 2025-12-31.
| Metric | PYPD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 7.9M | n/a | 15 |
| Operating margin | n/a | -283.9% | n/a | 13 |
| Net margin | n/a | -267.1% | n/a | 13 |
| Return on equity | -311.4% | -69.9% | 14 | 17 |
Peers (24): VYGR, BETRF, BDTX, CBUS, UNCY, ENGN, NERV, VTVT, NRXP, VANI, ANIX, OKUR, IMUX, VXRT, LENZ, TVGN, CLLS, FHTX, HUMA, ICCC, NTHI, AVXL, COYA, NRXS. Left out: TLSA (period gap). Fiscal periods ending between 2025-01-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (PYPD: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PYPD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PYPD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.